

ACCIDENTAL BOWEL LEAKAGE


Accidental Bowel Leakage (ABL), medically termed bowel or faecal incontinence, is a problem with higher prevalence than commonly assumed¹ that has a major impact on quality of life².

ABL patients deserve new treatment options that can help manage their symptoms, improve their quality of life and restore their dignity.

MARKET RESEARCH

Renew Medical, the manufacturer of Renew Inserts, commissioned a “mature women’s health survey,³” conducted by Nielsen (a global research and information organisation), which evaluated different health conditions and the relative rates of diagnosis versus experience of symptoms. Arthritis and hypertension are widely diagnosed conditions, yet continence and bowel conditions remain the unspoken health taboo.

In the female population, aged 45 plus, urinary incontinence is experienced by more than four times the number of women that are diagnosed with the condition. ABL shows a more marked problem, with the number of affected almost ten times the number of those diagnosed.




The survey also determined that 25% of ABL sufferers experience leakage on a daily or weekly basis. Furthermore, the survey also uncovered that 30% of urinary incontinence sufferers have ABL.

RENEW INSERTS


The Renew Insert is a new medical device that reduces ABL by forming a soft seal in the rectum. Renew Inserts are inserted using a disposable fingertip applicator.

Renew Medical has researched, developed and clinically tested the Renew Insert for more than seven years.

POSITION OF RENEW[®] INSERT



The Renew Insert softly seals inside the rectum.



RENEW INSERTS VS FOAM ANAL PLUGS

The Renew Insert occupies approximately 1/16th the volume in the rectum relative to a foam anal plug.

RENEW INSERTS:

78% of subjects who completed 12 weeks of treatment were **very or extremely satisfied** with the device⁴

Only **8%** of subjects withdrew due to dissatisfaction with the device⁴

FOAM ANAL PLUG:

“The majority, **70%, could not tolerate** a plug due to discomfort”⁵

RENEW INSERTS CLINICAL PROGRAMME HIGHLIGHTS

US PIVOTAL CLINICAL TRIAL⁴

A clinical trial collected data on 91 subjects who used almost 19,000 Renew Inserts during a treatment period of 12 weeks of required continuous Insert use.

The median frequency of ABL was reduced by 82%.

78% of subjects had $\geq 50\%$ reduction in the frequency of ABL.

There were no serious adverse events related to use of Renew Inserts and of the reported adverse events, 97.6% were rated as mild.

Evaluations (DREs and anoscopies) of the anal canal and lower rectal mucosa were conducted pre and post treatment and showed no evidence of irritation of the anal canal or lower rectal mucosa in all subjects evaluated.

35 MONTH UK CONSUMER PANEL⁶

In a UK Consumer panel, 19 subjects participated in a continuous usage evaluation. 11 completed consistent use of Renew Inserts for 35 months.

Users reported an extremely high level of satisfaction with Renew Inserts with a 35 month average rating of 4.8 (on a 5-point scale, where 5 is extremely satisfied).

Subjects reported;

- ▶ an 80% decrease in solid and / or liquid faeces incontinence
- ▶ a 50% decrease in gas incontinence
- ▶ an 83% decrease in the frequency of use of pads or diapers to manage their condition
- ▶ a 75% decrease in ABL impacting their quality of life